Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Twice-Yearly shot help kids with rare high cholesterol?

NCT ID NCT06597006

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests a drug called inclisiran in children aged 2 to 12 who have a rare genetic condition that causes extremely high cholesterol. The goal is to see if the drug safely lowers their bad cholesterol compared to a placebo. Participants will receive either inclisiran or placebo for one year, then all will receive inclisiran for a second year.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA - HOMOZYGOUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis cardiovascular disorder Dyslipidemias heart failure homozygous familial hypercholesterolemia Hypercholesterolemia hyperlipidemia Hyperlipoproteinemia Type II

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL HYPERCHOLESTEROLEMIA - HOMOZYGOUS

Contacts and locations

Locations

  • Childrens National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • Novartis Investigative Site

    RECRUITING

    Vienna, 1090, Austria

  • Novartis Investigative Site

    RECRUITING

    Beijing, Beijing Municipality, 100013, China

  • Novartis Investigative Site

    RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    RECRUITING

    Ioannina, 455 00, Greece

  • Novartis Investigative Site

    RECRUITING

    Thessaloniki, 546 42, Greece

  • Novartis Investigative Site

    RECRUITING

    Kota Bharu, Kelantan, 16150, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Amsterdam, North Holland, 1105 AZ, Netherlands

  • Novartis Investigative Site

    RECRUITING

    Bloemfontein, Free State, 9301, South Africa

  • Novartis Investigative Site

    RECRUITING

    Johannesburg, Gauteng, 2193, South Africa

  • Novartis Investigative Site

    RECRUITING

    Taichung, 407219, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Taipei, 111045, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Adana, Saricam, 01330, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Ankara, Yenimahalle, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Izmir, 35100, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • Primary Childrens Medical Center

    RECRUITING

    Salt Lake City, Utah, 84113, United States

  • UC San Francisco Medical Center

    RECRUITING

    San Francisco, California, 94143-0348, United States

  • Washington Univ School Of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.